bi-907828
boehringer ingelheim
['bi 907828']
#aacr23 check out the first disclosure of our mdm2-p53 antagonist bi 907828 currently in clinical trials. a tour de force in medicinal chemistry. presented at 1.30 pm, poster lb003, section 34 by #mdm2 #ddlps p. sini and d. rudolph 
Global Head of Cancer Research @Boehringer. Focus on improving the lives of cancer patients.